Default: Thoracic Cancer

ISSN: 1759-7706

Journal Home

Journal Guideline

Thoracic Cancer Q2 Unclaimed

Blackwell Publishing Asia Pty Ltd Australia
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Thoracic Cancer is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 48. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1800 €. The scope of the journal is focused on treatment and research, Asia-Pacific, thoracic cancer, prevention. It has an SJR impact factor of 0,778 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,778.

Type: Journal

Type of Copyright: CC BY-NC

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

Price

1800 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Thoracic Cancer

0,778

SJR Impact factor

48

H Index

400

Total Docs (Last Year)

1370

Total Docs (3 years)

11826

Total Refs

3712

Total Cites (3 years)

1310

Citable Docs (3 years)

2.36

Cites/Doc (2 years)

29.57

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


Treatment and research Asia-Pacific Thoracic cancer Prevention



Best articles by citations

Validation of the Mandarin Chinese version of the Leicester Cough Questionnaire in non-small cell lung cancer patients after surgery

View more

Spontaneous regression of non-small cell lung cancer that progressed after multiple chemotherapies: A case report

View more

Metastases of basal-like breast invasive ductal carcinoma to the endometrium: A case report and review of the literature

View more

Rapidly growing pleural liposarcoma masquerading as extrapleural hematoma

View more

Substernal hand-assisted videothoracoscopic lung metastasectomy: Long term results in a selected patient cohort

View more

Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis

View more

Solitary pulmonary metastasis from malignant melanoma of the bulbar conjunctiva presenting as a pulmonary ground glass nodule: Report of a case

View more

Metastasis in the subcarinal lymph node with unknown primary tumor

View more

Clinical experiences with molecular targeted therapy in lung cancer in China

View more

Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy

View more

Mixed-type primary germ cell tumor of the mediastinum in a young adult male with a sudden life threatening condition: A case report

View more

Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC

View more
SHOW MORE ARTICLES

Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib

View more

Characterization of solitary pulmonary nodules using double phase Tc-99m methoxyisobutylisonitrile scan: Comparison of visual and quantitative analyses

View more

Management of post-pneumonectomy syndrome using tissue expanders

View more

Human leukocyte antigen(HLA)-Ggene polymorphism in patients with non-small cell lung cancer

View more

Preferred surgical procedure for posterior mediastinal neurogenic tumor

View more

Prognostic impact of examined lymph node count in pT1N0M0 esophageal cancer: A population-based study

View more

Circulating plasma lncRNAs as novel markers of

View more

Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance

View more

Management of immune checkpoint inhibitor-related rheumatic adverse events

View more

Prevalence of low body mass index among newly diagnosed lung cancer patients in North India and its association with smoking status

View more

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy

View more

A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer

View more

FAQS